Pancreatic Tumors Can Spread Years After Surgery

Patients with pancreatic neuroendocrine tumors who had no visible spread at surgery may still develop metastases later.

Updated on Nov. 5, 2026 in Cancer

Pancreatic Tumors Can Spread Years After Surgery

Researchers presented a retrospective study of 208 patients with pancreatic neuroendocrine tumors at the 2026 NANETS symposium in Las Vegas. Nearly 20% of patients who had their tumors surgically removed without visible spread developed metastases within four years, which is relevant to people managing this rare cancer and their follow-up care.

Why it matters

The findings give patients and clinicians a clearer picture of how often pancreatic neuroendocrine tumors return or spread after surgery, which shapes how closely patients are monitored. The data come from a single institution's records, so they describe one patient population rather than the full national picture.

This retrospective analysis of 208 patients from a single-institution database covering 2000 to 2024 reported that 18.7% of patients without metastasis at surgery later developed it, at a median follow-up of 65 months. The design cannot establish cause, and results from one center may not reflect other patient populations.

The players

NANETS

The North American Neuroendocrine Tumor Society is a professional organization that advances research, education, and care for patients with neuroendocrine tumors.

The details

Pancreatic neuroendocrine tumors arise from hormone-producing cells in the pancreas and can sometimes spread, most often to the liver. In this cohort, liver involvement was the most common site of spread, appearing in 95.3% of patients who had metastasis at presentation and 82.6% of those who developed it later. Patients who were without visible spread at surgery but later developed metastasis did so at a median of 42 months after resection, which is why long-term follow-up matters.

Timeline

  1. Patient data were collected in a single-institution database covering 2000 to 2024.

  2. Patients had a median follow-up of 65 months after initial treatment.

  3. The median time to metastasis for patients who initially had no spread was 42 months after resection.

  4. The findings were presented at the NANETS 2026 symposium on November 5-7, 2026.

Health Landscape

Pancreatic neuroendocrine tumors are rare, and clinicians rely on long-term follow-up data from specialist centers to guide surveillance after surgery. This single-institution cohort adds to that body of evidence on how often patients who appear cured go on to develop metastasis years later.

If you have had surgery for a pancreatic neuroendocrine tumor, this study is a reminder that follow-up imaging and monitoring can continue for years, so it is worth asking your oncology team how long your surveillance schedule should run. Anyone with a history of this tumor should discuss their individual risk and monitoring plan with their physician rather than changing care based on a single study.

The takeaway

Nearly one in five patients whose tumors appeared confined to the pancreas at surgery developed spread within about four years in this cohort, underscoring the value of long-term follow-up. Ask your care team to explain your surveillance schedule and what symptoms or changes should prompt an earlier visit.

Further reading

For broader background, explore our Cancer coverage on how tumors spread and how survivors are followed over time.